Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Minority Interest (2021 - 2023)

Zentalis Pharmaceuticals has reported Minority Interest over the past 3 years, most recently at $107000.0 for Q4 2023.

  • For Q4 2023, Minority Interest fell 51.58% year-over-year to $107000.0; the TTM value through Dec 2023 reached $107000.0, down 51.58%, while the annual FY2023 figure was $107000.0, 51.58% down from the prior year.
  • Minority Interest for Q4 2023 was $107000.0 at Zentalis Pharmaceuticals, down from $129000.0 in the prior quarter.
  • Over five years, Minority Interest peaked at $528000.0 in Q4 2021 and troughed at $107000.0 in Q4 2023.
  • A 3-year average of $248777.8 and a median of $221000.0 in 2022 define the central range for Minority Interest.
  • Biggest five-year swings in Minority Interest: crashed 58.14% in 2022 and later plummeted 44.87% in 2023.
  • Year by year, Minority Interest stood at $528000.0 in 2021, then crashed by 58.14% to $221000.0 in 2022, then plummeted by 51.58% to $107000.0 in 2023.
  • Business Quant data shows Minority Interest for ZNTL at $107000.0 in Q4 2023, $129000.0 in Q3 2023, and $141000.0 in Q2 2023.